Document text
Principal Investigator: Barton F. Haynes
Organization: DUKE UNIVERSITY
Fiscal Year: 2020
Award: $4,527,376
Funding agency: National Institute of Allergy and Infectious Diseases
A key goal of HIV-1 vaccine development is to induce long-lasting broadly neutralizing antibodies (bnAbs)
that can inhibit HIV-1 infection. Messenger (m) RNA has emerged as a promising new vaccine modality that
can elicit potent immune responses, while avoiding the safety risks and anti-vector immunity associated with
some live virus vaccines. Important targets for bnAb induction are N301, N332 glycans at the base of the
gp120 V3 loop. Our overall goals in this grant are 1) To design an mRNA that encodes a V3-glycan
mimetope that, when expressed, will bind a V3 glycan UCA; 2) To select and produce mRNA formulations
non-GMP that encode HIV-1 Envs for immunization in humanized mice and RMs; and 3) To produce the
sequential V3-glycan mRNA vaccine under CGMP conditions, perform toxicity studies, and prepare an IND for
testing in a Phase I trial in man.
Overall Specific Aim 1. Develop mRNA delivery constructs for sequential Env trimers for V3-glycan
bnAb B cell lineage vaccinations.
Hypotheses: Messenger RNA vaccination of humanized mice, Rhesus macaques and humans will induce
long-lasting anti-V3 glycan bnAb epitope antibodies, and mRNA vaccination will promote sequential somatic
hypermutations and affinity maturation in V3-glycan targeted B cell lineages.
Overall Specific Aim 2. Produce CGMP mRNA immunogens.
Hypotheses: Messenger RNAs can be produced and encapsulated in potent nanoparticle formulations under
CGMP for use in human Phase I trials, and will be safe and immunogenic. Moreover, the mRNA immunogens
selected for CGMP production will produce stable Env trimers upon transfection of cell lines in vitro and after
immunization in vivo in humanized mice.
Expectations and Impact on the Field. Messenger RNAs are the current most promising vaccine strategy for
inducing high-titered and long-lasting antibody responses. A successful first in man Phase I clinical trial with
clinical trials materials produced in this IPCAVD will change the field by showing the plausibility of initiation of
V3-glycan bnAb B cell lineages.
Terms: <AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Affinity><Antibodies><Antibody Response><Antigenic Determinants><Antigens><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Binding><Binding Determinants><Cell Line><Cell Lineage><CellLine><Clinical Trials><Contracting Opportunities><Contracts><Doctor of Philosophy><Early-Stage Clinical Trials><Encapsulated><Epitopes><Formulation><Glycans><Glycopeptides><Goals><Grant><HIV><HIV Envelope Glycoprotein gp120><HIV Envelope Protein gp120><HIV env Protein gp120><HIV-1><HIV-1 vaccine><HIV-I><HIV1><HIV1 vaccine><HTLV-III gp120><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Ig Somatic Hypermutation><Immune response><Immunity><Immunization><Immunoglobulin Somatic Hypermutation><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunostimulation><In Vitro><Infection><Investigational New Drug Application><LAV-HTLV-III><Lead><Letters><Lymphadenopathy-Associated Virus><M mulatta><M. mulatta><Macaca mulatta><Messenger RNA><Mice><Mice Mammals><Modality><Modern Man><Molecular Interaction><Murine><Mus><NIH Vaccine Research Center><Non-Polyadenylated RNA><Nucleosides><Pb element><Ph.D.><PhD><Phase 1 Clinical Trials><Phase I Clinical Trials><Polysaccharides><Process><Production><RNA><RNA Gene Products><RNA vaccine><Regimen><Rhesus Macaque><Rhesus Monkey><Ribonucleic Acid><Risk><Safety><Site><Strains Cell Lines><Technology><Testing><Therapeutic><Toxic effect><Toxicities><Transfection><V3 Loop><V3 Loop of HIV-1><Vaccination><Vaccines><Virus><Virus-HIV><Work><Writing><base><cultured cell line><design><designing><develop a vaccine><development of a vaccine><expectation><experiment><experimental research><experimental study><first in man><first-in-human><gp120><gp120 ENV Glycoprotein><gp120(HIV)><heavy metal Pb><heavy metal lead><host response><humanized mice><humanized mouse><immunogen><immunogenic><immunogenicity><immunoresponse><in vivo><lipid nanoparticle><mRNA><mRNA delivery><mRNA vaccine><man><man's><meetings><member><nano particle><nano-sized particle><nanoparticle><nanosized particle><neutralizing antibody><new vaccines><next generation vaccines><novel vaccines><phase 1 trial><phase I protocol><phase I trial><programs><somatic hypermutation><vaccine development><vaccine formulation><vector>